Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅,且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性,也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。
Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅,且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性,也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.